About: COVID-19 in rheumatic diseases: A random cross-sectional telephonic survey

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 in rheumatic diseases: A random cross-sectional telephonic survey Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	COVID-19 in rheumatic diseases: A random cross-sectional telephonic survey
Creator	Affiliations, Goswami, Rudra Bhadu, Danveer Kanjilal, Maumita Kumar, Uma Meena, Laxman Mittal, Dheeraj Nagar, Sandeep Ray, Debaditya Vij, Pallavi
Source	MedRxiv
abstract	Objective. To describe the incidence, clinical course, and predictive factors of coronavirus 2019 (COVID-19) infection in a cohort of rheumatological patients residing in New Delhi (National Capital Region), India. Methods. We performed a cross-sectional, random telephonic survey from 20th April to 20th July 2020 on patients with rheumatic diseases. Patients were interviewed with a predesigned questionnaire. The incidence of COVID-19 in the general population was obtained from open access government data repository. Report of reverse transcriptase polymerase chain reaction report was taken as confirmatory of COVID-19 infection. Results. Among the 900 contacted patients 840 responded (713 with rheumatoid arthritis (RA), 100 with systemic lupus erythematosus (SLE), 20 with spondylarthritis (SpA) and 7 with others; mean age 45 years, mean duration 11.3 years; 86% female). Among them 29 reported flu-like symptoms and four RA patients had confirmed COVID-19 infection. All of them were hospitalized with uneventful recovery. Rheumatological drugs were discontinued during the infectious episode. Disease modifying agents and biologics were equally received by those with or without COVID-19. The incidence of COVID-19 was similar to general Delhi population (0.476% vs 0.519% respectively, p=0.86). Two patients had relapse of rheumatic disease after recovery. After recovery from COVID-19 or Flu-like illness, eight patients (27.6%, 95% confidence interval 14.7-45.7) reported disease flare. Conclusion. Patients with rheumatic diseases in India have similar incidence of COVID-19 infection compared to the community. Relapse of underlying rheumatic disease after recovery is not uncommon and continuation of glucocorticoid through the infection should be considered.
has issue date	2020-08-13(xsd:dateTime)
bibo:doi	10.1101/2020.08.09.20170985
has license	medrxiv
sha1sum (hex)	21196810c7953eed2f697cccdd5c07b1d93323a1
schema:url	https://doi.org/10.1101/2020.08.09.20170985
resource representing a document's title	COVID-19 in rheumatic diseases: A random cross-sectional telephonic survey
resource representing a document's body	covid:21196810c7953eed2f697cccdd5c07b1d93323a1#body_text
is schema:about of	named entity 'incidence' named entity 'COVID-19' named entity 'preprint' named entity 'SLE' named entity 'infection' named entity 'cross-sectional' named entity 'Running' named entity 'New Delhi' named entity 'coronavirus 2019' named entity 'National Capital Region' named entity 'COVID-19' named entity 'rheumatic diseases' named entity 'Running Head' named entity 'doi' named entity 'haematological' named entity 'peer review' named entity 'SPSS' named entity 'methotrexate' named entity 'peer review' named entity 'peer review' named entity 'cytokine storm' named entity 'Chi Squared test' named entity 'preprint' named entity 'virus' named entity 'peer review' named entity 'thrombosis' named entity 'institutional review board' named entity 'preprint' named entity 'COVID' named entity 'oxygen support' named entity 'medRxiv' named entity 'proteinuria' named entity 'preprint' named entity 'clinical features' named entity 'COVID19' named entity 'reviewed and approved' named entity 'mycophenolate' named entity 'rituximab' named entity 'COVID-19' named entity 'flu-like symptoms' named entity 'preprint' named entity 'preprint' named entity 'preprint' named entity 'rheumatological' named entity 'infection' named entity 'preprint' named entity 'immunosuppressive drugs' named entity 'SARS-CoV-2' named entity 'dexamethasone' named entity 'molecular mimicry' named entity 'medRxiv' named entity 'coronary artery disease' named entity 'preprint' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'Delhi' named entity 'creatinine' named entity 'August 13' named entity 'disease-modifying antirheumatic drugs' named entity 'COVID' named entity 'categorical data' named entity 'rT-PCR' named entity 'flu-like symptoms' named entity 'COVID-19' named entity 'Delhi' named entity 'induction therapy' named entity 'infection' named entity 'doi' named entity 'COVID' named entity 'rheumatologists' named entity 'respiratory viral infections' named entity 'Statistical methods' named entity 'COVID' named entity 'immunosuppressive drugs' named entity 'lupus' named entity 'demographic'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software